Correction in CELLINK’s Swedish press release
Earlier this morning at 07:00 (CET), CELLINK sent out a press release: CELLINK has entered into an agreement to acquire MatTek, the world-leading company in in vitro technology and alternative test methods for pharmaceuticals.
The Swedish press release states the word “patent-protected”, this word shall be changed to “proprietary” as corrected reflected in the English press release.
The information was submitted for publication, through the agency of the contact persons set out below, on March 10, 2021 at 09.16 (CET).
For further information, please contact:
|Erik Gatenholm, CEO Phone (Sweden): +46 73 267 00 00Phone (US): +1 (650) 515 5566Email: email@example.com||Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138Email: firstname.lastname@example.org
Founded in 2016, CELLINK is the leading bioconvergence company in world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors